Safety and efficacy of an all-oral interferon-free regimen of seraprevir, an NS3/4A protease inhibitor and sofosbuvir in patients with chronic hepatitis C virus (HCV) genotype 1: an open-label, multicentre, phase 3 trial

被引：0

作者：

Wen, Xiaoyu ^{[1
]}

Kong, Fei ^{[1
]}

Wen, Xiaofeng ^{[2
]}

Wang, Xiaozhong ^{[3
]}

Lin, Shide ^{[4
]}

Wu, Guicheng ^{[5
]}

Wang, Li ^{[6
]}

Xing, Huichun ^{[7
]}

Yan, Xuebing ^{[8
]}

Zheng, Sujun ^{[9
]}

Ning, Qin ^{[10
]}

Wang, Zheng ^{[11
]}

Zhang, Liaoyun ^{[12
]}

Li, Jianmei ^{[13
]}

Tong, Zhaowei ^{[14
]}

Su, Minghua ^{[15
]}

Tong, Lixin ^{[16
]}

Huang, Chengyu ^{[17
]}

Jia, Ji-Dong ^{[18
]}

Xin, Yongning ^{[19
]}

Zhu, Qingjing ^{[20
]}

Wang, Jing ^{[21
]}

Zhang, Yuexin ^{[22
]}

Li, Guangming ^{[23
]}

Niu, Junqi ^{[1
]}

机构：

[1] First Hosp Jilin Univ, Hepatol, Changchun, Peoples R China

[2] Liuzhou Peoples Hosp, Liuzhou, Peoples R China

[3] Xinjiang Uygur Autonomous Reg Tradit Chinese Med, Tibetan, Peoples R China

[4] Zunyi Med Coll, Affiliated Hosp, Zunyi, Guizhou, Peoples R China

[5] Chongqing Three Gorges Cent Hosp, Chongqing, Peoples R China

[6] Chengdu Publ Clin Hlth & Med Ctr, Chengdu, Peoples R China

[7] Capital Med Univ, Beijing Ditan Hosp, Beijing, Peoples R China

[8] Xuzhou Med Univ, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China

[9] Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China

[10] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China

[11] Fifth Hosp Wuxi, Wuxi, Jiangsu, Peoples R China

[12] Shanxi Med Univ, Hosp 1, Jinzhong, Peoples R China

[13] Sichuan Prov Peoples Hosp, Chengdu, Peoples R China

[14] Huzhou City Cent Hosp, Huzhou, Peoples R China

[15] Guangxi Med Univ, Hosp 1, Nanning, Peoples R China

[16] Hebei Med Univ, Hosp 1, Shijiazhuang, Hebei, Peoples R China

[17] Chongqing Publ Clin Hlth & Med Ctr, Chongqing, Peoples R China

[18] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China

[19] Qingdao City Cent Hosp, Qingdao, Peoples R China

[20] Jinyintan Hosp Wuhan, Wuhan, Peoples R China

[21] Southwest Med Univ, Tradit Chinese Med Hosp, Luzhou, Peoples R China

[22] Xinjiang Med Univ, Hosp 1, Urumqi, Peoples R China

[23] Zhengzhou Sixth Peoples Hosp, Zhengzhou, Peoples R China

来源：

JOURNAL OF HEPATOLOGY | 2020年 / 73卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

THU391

引用

页码：S330 / S330

页数：1

共 50 条

[41] A PHASE 3, RANDOMISED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 8 AND 12 WEEKS OF SIMEPREVIR (SMV) PLUS SOFOSBUVIR (SOF) IN TREATMENT-NAIVE AND -EXPERIENCED PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION WITHOUT CIRRHOSIS: OPTIMIST-1
Kwo, P.
Gitlin, N.
Nahass, R.
Bernstein, D.
Rojter, S.
Schiff, E.
Davis, M.
Ruane, P. J.
Younes, Z.
Kalmeijer, R.
Peeters, M.
Lenz, O.
Fevery, B.
De La Rosa, G.
Scott, J.
Sinha, R.
Witek, J.
JOURNAL OF HEPATOLOGY, 2015, 62 : S270 - S270
[42] Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants
Wu, Jing
Giessmann, Thomas
Lang, Benjamin
Elgadi, Mabrouk
Huang, Fenglei
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2016, 68 (04) : 459 - 466
[43] SUSTAINED VIRAL RESPONSE (SVR) RATES IN GENOTYPE 1 TREATMENT-NAiVE PATIENTS WITH CHRONIC HEPATITIS C (CHC) INFECTION TREATED WITH VANIPREVIR (MK-7009), A NS3/4A PROTEASE INHIBITOR, IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN FOR 28 DAYS
Manns, Michael P.
Gane, Edward J.
Rodriguez-Torres, Maribel
Stoehr, Albrecht D.
Yeh, Chau-Ting
Marcellin, Patrick
Wiedmann, Richard T.
Hwang, Peggy
Barnard, Richard J.
Lee, Andrew W.
HEPATOLOGY, 2010, 52 (04) : 361A - 361A
[44] EARLY VIRAL RESPONSE (EVR) RATES IN TREATMENT-NAiVE PATIENTS WITH CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION TREATED WITH MK-7009, A NOVEL NS3/4A PROTEASE INHIBITOR, IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN FOR 28 DAYS
Manns, Michael P.
Gane, Edward J.
Rodriguez-Torres, Maribel
Stoehr, Albrecht D.
Yeh, Chau-Ting
Marcellin, Patrick
Wiedmann, Richard T.
Hwang, Peggy
Barnard, Richard J.
Quirk, Erin
Kartsonis, Nicholas A.
Lee, Andrew W.
HEPATOLOGY, 2009, 50 (04) : 332A - 333A
[45] Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: A phase 1b multiple ascending dose study
Forestier, Nicole
Larrey, Dominique
Guyader, Dominique
Marcellin, Patrick
Rouzier, Regine
Patat, Alain
Smith, Patrick
Bradford, Williamson
Porter, Steven
Blatt, Lawrence
Seiwert, Scott D.
Zeuzem, Stefan
JOURNAL OF HEPATOLOGY, 2011, 54 (06) : 1130 - 1136
[46] Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial
Mizokami, Masashi
Yokosuka, Osamu
Takehara, Tetsuo
Sakamoto, Naoya
Korenaga, Masaaki
Mochizuki, Hitoshi
Nakane, Kunio
Enomoto, Hirayuki
Ikeda, Fusao
Yanase, Mikio
Toyoda, Hidenori
Genda, Takuya
Umemura, Takeji
Yatsuhashi, Hiroshi
Ide, Tatsuya
Toda, Nobuo
Nirei, Kazushige
Ueno, Yoshiyuki
Nishigaki, Yoichi
Betular, Juan
Gao, Bing
Ishizaki, Akinobu
Omote, Masa
Mo, Hongmei
Garrison, Kim
Pang, Phillip S.
Knox, Steven J.
Symonds, William T.
McHutchison, John G.
Izumi, Namiki
Omata, Masao
LANCET INFECTIOUS DISEASES, 2015, 15 (06): : 645 - 653
[47] A PHASE 3, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 12 WEEKS OF SIMEPREVIR (SMV) PLUS SOFOSBUVIR (SOF) IN TREATMENT-NAIVE OR -EXPERIENCED PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION AND CIRRHOSIS: OPTIMIST-2
Lawitz, E.
Matusow, G.
DeJesus, E.
Yoshida, E.
Felizarta, F.
Ghalib, R.
Godofsky, E.
Herring, R.
Poleynard, G.
Sheikh, A.
Tobias, H.
Kugelmas, M.
Kalmeijer, R.
Peeters, M.
Lenz, O.
Fevery, B.
De La Rosa, G.
Scott, J.
Sinha, R.
Witek, J.
JOURNAL OF HEPATOLOGY, 2015, 62 : S264 - S265
[48] SAFETY AND ANTIVIRAL ACTIVITY OF BI201335, A NEW HCV NS3 PROTEASE INHIBITOR, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE-1 INFECTION GIVEN AS MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA 2A (P) AND RIBAVIRIN (R)
Manns, Michael P.
Bourliere, Marc
Benhamou, Yves
Pol, Stanislas
Bonacini, Maurizio
Berg, Thomas
Trepo, Christian
Wright, David
Steinmann, Gerhard
Huang, David B.
Mikl, Jaromir
Kukolj, George
Stern, Jerry O.
HEPATOLOGY, 2008, 48 (04) : 1133A - 1133A
[49] Sofosbuvir/velpatasvir/voxilaprevir for 12 weeks is a safe and effective salvage regimen for NS5A inhibitor-experienced patients with genotype 1-6 hepatitis C virus infection: An integrated analysis of Phase 2 and Phase 3 studies
Thompson, A.
Manns, M. P.
Bourliere, M.
Stamm, L. M.
Hyland, R. H.
Ni, L.
Dvory-Sobol, H.
Brainard, D. M.
Subramanian, G. M.
Lawitz, E.
Gane, E. J.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 42 - 42
[50] An Interferon-free, Ribavirin-free 12-Week Regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 Yielded SVR4 of 94% in Treatment-Naive Patients with Genotype (GT) 1 Chronic Hepatitis C Virus (HCV) Infection
Everson, Gregory T.
Sims, Karen D.
Rodriguez-Torres, Maribel
Hezode, Christophe
Lawitz, Eric
Bourliere, Marc
Loustaud-Ratti, Veronique
Rustgi, Vinod K.
Schwartz, Howard
Tatum, Harvey A.
Marcellin, Patrick
Pol, Stanislas
Thuluvath, Paul J.
Eley, Timothy
Wang, Xiaodong
Huang, Shu-Pang
McPhee, Fiona
Wind-Rotolo, Megan
Chung, Ellen
Pasquinelli, Claudio
Grasela, Dennis M.
Gardiner, David F.
HEPATOLOGY, 2012, 56 (06) : 1517 - 1518

← 1 2 3 4 5 →